Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Natera Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NTRA
Nasdaq
2835
https://www.natera.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Natera Inc
New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
- Feb 2nd, 2023 1:01 pm
Raymond James Sees ‘Multiple Expansion’ to Drive Stock Market Returns — Here Are 2 Stocks to Play That Bullish Sentiment
- Jan 25th, 2023 12:42 am
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
- Jan 19th, 2023 1:02 pm
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
- Jan 18th, 2023 6:11 pm
Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
- Jan 17th, 2023 1:01 pm
Wall Street Analysts Think Natera (NTRA) Could Surge 82.88%: Read This Before Placing a Bet
- Jan 12th, 2023 2:55 pm
Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2023 9:05 pm
A Natera, Inc. (NASDAQ:NTRA) insider increased their holdings by 13% last year
- Jan 3rd, 2023 2:39 pm
Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients
- Dec 22nd, 2022 12:23 am
Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers
- Dec 9th, 2022 1:33 pm
After losing 58% in the past year, Natera, Inc. (NASDAQ:NTRA) institutional owners must be relieved by the recent gain
- Dec 7th, 2022 2:13 pm
Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium
- Dec 7th, 2022 1:33 pm
Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT
- Dec 6th, 2022 10:31 am
13 Best Genomics Stocks To Buy Now
- Dec 5th, 2022 8:49 pm
Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Nov 23rd, 2022 1:33 pm
Biotech companies Natera and Synthego are laying off a total of 163 employees
- Nov 22nd, 2022 11:14 pm
New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients
- Nov 21st, 2022 1:33 pm
Natera Announces Pricing of Follow-On Offering
- Nov 16th, 2022 4:01 am
Natera Launches Proposed Follow-On Offering
- Nov 15th, 2022 9:30 pm
Natera Third Quarter 2022 Earnings: Beats Expectations
- Nov 10th, 2022 10:56 am
Scroll